Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation

New England Journal of Medicine

Volumn 341, Issue 12, 1999, Pages 871-878

  Kudenchuk, Peter J ^a   Cobb, Leonard A ^a   Copass, Michael K ^b   Cummins, Richard O ^a   Doherty, Alidene M ^a   Fahrenbruch, Carol E ^a   Hallstrom, Alfred P ^b   Murray, William A ^a   Olsufka, Michele ^a   Walsh, Thomas ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fire Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATION; DRUG EFFICACY; FEMALE; HEART VENTRICLE FIBRILLATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESUSCITATION; SURVIVAL RATE;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; CARDIOPULMONARY RESUSCITATION; DOUBLE-BLIND METHOD; ELECTRIC COUNTERSHOCK; EMERGENCY MEDICAL SERVICES; FEMALE; HEART ARREST; HUMANS; MALE; MIDDLE AGED; SURVIVAL RATE; TACHYCARDIA; VENTRICULAR FIBRILLATION;

EID: 0033575997     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199909163411203     Document Type: Article

References (42)

1. National Center for Health Statistics. Report of final mortality statistics, 1995. Mon Vital Stat Rep 1997;45(11):Suppl 2.
2. Gillum RF. Sudden coronary death in the United States: 1980-1985. Circulation 1989;79:756-65.
3. Cummins RO, ed. Advanced cardiac life support. Dallas: American Heart Association, 1997:1-17.
4. Advanced Life Support Working Party of the European Resuscitation Council. Guidelines for advanced life support: a statement by the Advanced Life Support Working Party of the European Resuscitation Council, 1992. Resuscitation 1992;24:111-21.
5. Weaver WD. Resuscitation outside the hospital - what's lacking? N Engl J Med 1991;325:1437-9.
6. Jaffe AS. The use of antiarrhythmics in advanced cardiac life support. Ann Emerg Med 1993;22:307-16.
7. Cobb LA, Hallstrom AP. Community-based cardiopulmonary resuscitation: what have we learned? Ann N Y Acad Sci 1982;382:330-42.
8. Emerman CL, Pinchak AC, Hancock D, Hagen JF. The effect of bolus injection on circulation times during cardiac arrest. Am J Emerg Med 1990;8:190-3.
9. Weaver WD, Cobb LA, Dennis D, Ray R, Hallstrom AP, Copass MK. Amplitude of ventricular fibrillation waveform and outcome after cardiac arrest. Ann Intern Med 1985;102:53-5.
10. Federal policy for the protection of human subjects: notices and rules (45CFR46). Fed Regist 1991;56(117):28003-32.
11. Cobb LA, Weaver WD, Fahrenbruch CE, Hallstrom AP, Copass MK. Community-based interventions for sudden cardiac death: impact, limitations and changes. Circulation 1992;85:Suppl:I-98-I-102.
12. Cox SV, Woodhouse SP, Weber M, Boyd P, Case C. Rhythm changes during resuscitation from ventricular fibrillation. Resuscitation 1993;26: 53-61.
13. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Controlled Clin Trials 1984;5:348-61.
14. Babbs CF, Yim GKW, Whistler SJ, Tacker WA, Geddes LA. Elevation of ventricular defibrillation threshold in dogs by antiarrhythmic drugs. Am Heart J 1979;98:345-50.
15. Yoon MS, Han J, Goel BG, Creamer P. Effect of procainamide on fibrillation threshold of normal and ischemic ventricles. Am J Cardiol 1974; 33:238-42.
16. Echt DS, Black JN, Barbey JT, Coxe DR, Cato E. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs: sodium channel block and action potential prolongation. Circulation 1989;76:1106-17.
17. Kerber RE, Pandian NG, Jensen SR, et al. Effect of lidocaine and bretylium on energy requirements for transthoracic defibrillation: experimental studies. J Am Coll Cardiol 1986;7:397-405.
18. Dorian P, Fain ES, Davy JM, Winkle RA. Lidocaine causes a reversible, concentration-dependent increase in defibrillation energy requirements. J Am Coll Cardiol 1986;8:327-32.
19. Tacker WA, Niebauer JM, Baggs CF, et al. The effect of new antiarrhythmic drugs on defibrillation threshold. Crit Care Med 1980;8:177-80.
20. Herlitz J, Ekstrom L, Wennerblom B, et al. Lidocaine in out-of-hospital ventricular fibrillation: does it improve survival? Resuscitation 1997; 33:199-205.
21. Harrison EE. Lidocaine in prehospital countershock refractory ventricular fibrillation. Ann Emerg Med 1981;10:420-3.
22. Weaver WD, Fahrenbruch CE, Johnson DD, Hallstrom AP, Cobb LA, Copass MK. Effect of epinephrine and lidocaine therapy on outcome after cardiac arrest due to ventricular fibrillation. Circulation 1990;82: 2027-34.
23. van Walraven C, Stiell IG, Wells GA, Hebert PC, Vandemheen K. Do advanced cardiac life support drugs increase resuscitation rates from in-hospital cardiac arrest? Ann Emerg Med 1998;32:544-53.
24. Haynes RE, Chinn TL, Copass MK, Cobb LA. Comparison of bretylium tosylate and lidocaine in management of out of hospital ventricular fibrillation: a randomized clinical trial. Am J Cardiol 1981;48:353-6.
25. Olson DW, Thompson BM, Darin JC, Milbrath MH. A randomized comparison study of bretylium tosylate and lidocaine in resuscitation of patients from out-of-hospital ventricular fibrillation in a paramedic system. Ann Emerg Med 1984;13:807-10.
26. Nowak RM, Bodnar TJ, Dronen S, Gentzkow G, Tomlanovich MC. Bretylium tosylate as initial treatment for cardiopulmonary arrest: randomized comparison with placebo. Ann Emerg Med 1981;10:404-7.
27. Stiell IG, Wells GA, Hebert PC, Laupacis A, Weitzman BN. Association of drug therapy with survival in cardiac arrest: limited role of advanced cardiac life support drugs. Acad Emerg Med 1995;2:264-73.
28. Thel MC, Armstrong AL, McNulty SE, Califf RM, O'Connor CM. Randomised trial of magnesium in in-hospital cardiac arrest. Lancet 1997; 350:1272-6.
29. Fatovich DM, Prentice DA, Dobb GJ. Magnesium in cardiac arrest: the magic trial. Resuscitation 1997;35:237-41.
30. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-7.
31. Weaver WD, Cobb LA, Hallstrom AP, et al. Considerations for improving survival from out-of-hospital cardiac arrest. Ann Emerg Med 1986; 15:1181-6.
32. Weston CFM, Wilson RJ, Jones SD. Predicting survival from out-of-hospital cardiac arrest: a multivariate analysis. Resuscitation 1997;34:27-34.
33. Scheinman MM, Levine JH, Cannom DS, et al. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. Circulation 1995;92:3264-72.
34. Platou ES, Refsum H. Acute electrophysiologic and blood pressure effects of amiodarone and its solvent in the dog. Acta Pharmacol Toxicol (Copenh) 1986;58:163-8.
35. Gough WB, Zeiler RH, Barreca P, El-Sherif N. Hypotensive action of commercial intravenous amiodarone and polysorbate 80 in dogs. J Cardiovasc Pharmacol 1982;4:375-80.
36. Sicart M, Besse P, Choussat A, Bricaud H. Action hemodynamique de l'amiodarone intra-veineuse chez l'homme. Arch Mal Coeur Vaiss 1977;70: 219-27.
37. Munoz A, Karila P, Gallay P, et al. A randomized hemodynamic comparison of intravenous amiodarone with and without Tween 80. Eur Heart J 1988;9:142-8
38. Singh BN, Venkatesh N, Nademanee K, Josephson MA, Kannan R. The historical development, cellular electrophysiology and pharmacology of amiodarone. Prog Cardiovasc Dis 1989;31:249-80.
39. Kowey PR, Levine JH, Herre JM, et al. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. Circulation 1995;92:3255-63.
40. Emerman CL, Pinchak AC, Hancock D, Hagen JF. Effect of injection site on circulation times during cardiac arrest. Crit Care Med 1988;16: 1138-41.
41. Kuhn GJ, White BC, Swetman RE, et al. Peripheral vs central circulation times during CPR: a pilot study. Ann Emerg Med 1981;10:417-9.
42. Martin TG, Hawkins NS, Weigel JA, Rider DE, Buckingham BD. Initial treatment of ventricular fibrillation: defibrillation or drug therapy. Am J Emerg Med 1988;6:113-9.1